Fosamax and Osteonecrosis of the Jaw: Examining the Scientific Evidence

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Education to Targeted Risk Assessment

The legacy of general health and science information has long served as a foundation for public understanding of medical conditions and treatments. Within this broad context, discussions of bone health and osteoporosis management have been standard, often focusing on lifestyle factors and therapeutic interventions. As this informational heritage evolved, it began to incorporate more specialized topics, including the pharmacological profiles of medications used in chronic disease management. A natural progression from this general health framework leads to a focused examination of specific pharmaceutical agents and their potential unintended effects. In the domain of mass production, where consistency and safety are paramount, the transition from broad health education to occupational exposure concerns becomes particularly relevant. This shift involves moving from population-level health guidance to the scrutiny of how manufactured products may interact with biological systems in ways not fully anticipated during initial development.

Bridging General Health to Specific Drug Safety

The bridge concept here is the recognition that medications produced at scale, such as bisphosphonates, carry implications beyond their intended therapeutic use. This awareness prompts a pivot toward understanding how exposure to such agents—whether through patient administration or occupational contact in production settings—may correlate with rare but serious adverse events. The focus thus narrows from general health maintenance to the specific risk profile associated with Fosamax and its potential link to osteonecrosis of the jaw, setting the stage for a detailed examination of causation without delving into mechanistic claims.

Fosamax and Osteonecrosis of the Jaw: Evidence and Risk Factors

Fosamax (alendronate) is a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The optimal duration of use has not been determined, and for patients at low risk for fracture, consideration of drug discontinuation after 3 to 5 years of use is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a condition characterized by exposed, non-healing bone in the maxillofacial region, which can occur spontaneously but is generally associated with tooth extraction and/or local infection with delayed healing (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). ONJ has been reported in patients taking bisphosphonates, including Fosamax (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal and/or other pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with duration of exposure to bisphosphonates (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Mechanistic Pathways and Clinical Observations

The mechanistic pathways linking Fosamax to ONJ involve the drug's pharmacological action on bone remodeling. Bisphosphonates like alendronate inhibit osteoclast-mediated bone resorption, which can suppress normal bone turnover. In the jawbone, this suppression may impair the healing response to microtrauma or dental procedures, leading to avascular necrosis. Multiscale characterization of jawbone treated with osteoporosis therapeutic agents, including bisphosphonate (alendronate), has provided comprehensive information to help understand jawbone-specific responses to bone-related complications, including bisphosphonate-related osteonecrosis of the jaw (https://pubmed.ncbi.nlm.nih.gov/40345077/). Studies in estrogen-deficient rats have examined the effects of alendronate on jawbone properties, including static and dynamic mechanical stability of teeth in the alveolar socket, tissue mineral density distribution, and nanoindentation properties of the jawbone matrix (https://pubmed.ncbi.nlm.nih.gov/40345077/). These investigations contribute to understanding how bisphosphonate treatment may alter jawbone structure and function, potentially predisposing to ONJ. Regarding the timeline between exposure and documented harm, the time to onset of symptoms varied from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Most patients had relief of symptoms after stopping the drug, while a subset had recurrence of symptoms when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with these symptoms were similar in the Fosamax and placebo groups (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Adequacy of Warnings and Causation Considerations

The adequacy of warnings regarding Fosamax and ONJ is addressed in the prescribing information. The label includes a specific section on osteonecrosis of the jaw, describing the condition, associated risk factors, and the potential for increased risk with longer exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The label also notes that ONJ can occur spontaneously and is generally associated with dental procedures or local infection (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, the label does not provide specific guidance on monitoring or screening for ONJ in asymptomatic patients. For causation-related considerations, affected patients should be aware that ONJ has been reported in association with bisphosphonate use, including Fosamax, but the condition is rare and often linked to additional risk factors such as dental procedures or cancer therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56; https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The presence of ONJ does not necessarily imply causation by Fosamax alone, as spontaneous cases occur and other risk factors may contribute. Patients who develop ONJ while on Fosamax should discuss with their healthcare provider the potential benefits and risks of continuing or discontinuing the medication, especially if invasive dental procedures are planned. In summary, scientific evidence connects Fosamax to osteonecrosis of the jaw through reported adverse effects, mechanistic understanding of bisphosphonate action on bone remodeling, and clinical observations of ONJ in patients taking the drug. The prescribing information includes warnings about this risk, and the timeline for symptom onset can range from days to months after starting treatment. For affected patients, careful consideration of risk factors and dental management is warranted.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the scientific evidence linking Fosamax to osteonecrosis of the jaw?

Scientific evidence includes reported adverse effects in patients taking Fosamax, mechanistic understanding of bisphosphonate action on bone remodeling, and clinical observations of ONJ. The prescribing information warns about this risk, and studies have characterized jawbone changes in animal models (https://pubmed.ncbi.nlm.nih.gov/40345077/).

What are the risk factors for developing osteonecrosis of the jaw while on Fosamax?

Risk factors include invasive dental procedures, cancer diagnosis, concomitant therapies (chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, pre-existing dental disease, anemia, coagulopathy, infection, and ill-fitting dentures. Duration of bisphosphonate use may also increase risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.